Daraxonrasib · Rasonque
Small molecule
Evidence outlook
Approved: Pancreatic Ductal Adenocarcinoma (label: metastatic disease after at least one prior systemic therapy, or not a candidate for multiagent...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 3
Company guidance: topline data expected in 2027 (NCT06881784; Revolution Medicines, 5 Aug 2026). “Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RASolute 302 NCT06625320 · Pancreatic Ductal Adenocarcinoma Patients were randomly assigned to daraxonrasib or chemotherapy, but patients and doctors knew which treatment was given. The primary endpoints, overall survival and progression read by a blinded independent central reviewer, cannot be changed by that knowledge, and both improved significantly with daraxonrasib (overall survival hazard ratio 0.40, P<0.001). Registry: NCT06625320 | 3 | Progression free survival (PFS) in the RAS G12-mutant population (Up to approximately 3 years); Overall survival (OS) in the RAS G12-mutant population (Up to approximately 3 years) 2026-06 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other pan-RAS drugs
Other RAS (pan-RAS, RAS-mutant tumors) drugs
BPI-572270, RG6505. Compare all 3 RAS (pan-RAS, RAS-mutant tumors) drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Pancreatic Ductal Adenocarcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Daraxonrasib (Rasonque): this drug | Approved | Small molecule | pan-RAS, RAS (pan-RAS, RAS-mutant tumors) | Partial signal | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| INCB161734 | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Quemliclustat | Phase 3 | Small molecule | CD73 (NT5E) | not yet graded | No reviewed efficacy summary in this indication | |
| Setidegrasib | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Navlimetostat | Phase 2/3 | Small molecule | PRMT5 (protein arginine methyltransferase 5), MTA-cooperative binding | not yet graded | No reviewed efficacy summary in this indication | |
| Autogene Cevumeran | Phase 2 | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| ERAS-0015 | Phase 2 | Small molecule | pan-RAS | not yet graded | No reviewed efficacy summary in this indication | |
| GFH375 | Phase 2 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Nuzefatide Pevedotin | Phase 2 | Peptide | EphA2 | not yet graded | No reviewed efficacy summary in this indication | |
| ARV-806 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Vopimetostat | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK41959 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| RG6505 | —(overall) | Undisclosed | RAS (pan-RAS, RAS-mutant tumors) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rasonque (Daraxonrasib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
May 2027 (1)
What to watch
June 2027 (2)
December 2027 (1)
Company guidance: topline data expected in 2027 (Revolution Medicines, 5 Aug 2026). “Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.” Source ↗
What to watch
2028 (5)
April 2028 (2)
August 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (6)
February 2029 (1)
What to watch
March 2029 (1)
What to watch
May 2029 (2)
June 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (1)
November 2030 (1)
What to watch
2032 (1)
April 2032 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent